LGD-6972 (LGD6972; MB-11262) is a novel and orally bioavailable glucagon receptor antagonist with the potential to be used for treating type 2 diabetes (T2DM).

Lixisenatide (ZP10A; ZP-10A; AVE-0010; AVE0010; Lyxumia, Adlyxin) is a short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) with anti-diabetic effects.

Glucagon HCl is the mono-hydrochloride salt form of glucagon, which is an endogenous peptide hormone produced by pancreatic alpha cells.

NNC0640 is a novel and potent modulator of glucagon-like peptide-1 receptor (GLP-1R).

Semaglutide (NNC 0113-0217; NNC-0113-0217; Ozempic) is a novel and potent agonist of glucagon-like peptide-1 (GLP-1) receptor and belongs to the long-acting GLP-1 analogue.

Glucagon-Like Peptide (GLP) I (7-36), amide, human is a novel and potent physiological incretin hormone acting as glucose-dependent insulinotropic peptide produced by post-translational processing of proglucagon in intestinal L-cells.

Dulaglutide (Trulicity; LY2189265), glucagon-like peptide-1 receptor agonist (GLP-1 agonist).